Panacea Life Sciences Holdings (PLSH) Stock Analysis & Winston Score
Panacea Life Sciences Holdings is a small U.S. company that makes hemp-derived CBD products. Its lineup includes oils, capsules, topicals, and pet products sold mainly to everyday consumers through its website and select retail channels. The company operates in the specialty health and wellness space, competing in a crowded market alongside hundreds of other CBD brands. Panacea earns revenue primarily through direct-to-consumer online sales and some wholesale distribution. It is a very small company based in Colorado with a market cap near zero and has consistently lost money, as reflected in deeply negative margins. The CBD industry faces serious headwinds including unclear federal regulation from the FDA, intense price competition, and difficulty gaining shelf space at major retailers — all of which pose significant challenges to Panacea reaching profitability.
Winston Score: 20/100 — Weak
Weak fundamentals across most pillars.
- Quality: Weak (2/30)
- Growth: Weak (2/20)
- Cash Flow: Weak (0/10)
- Stability: Good (5/10)
- Valuation: Data not available (0/10)
- Ownership: Good (10/15)
Key Facts
Price: $0.07
Market Cap: $2M
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

